Skip to Content
Upcoming Webinar

repotrectinib (Augtyro®) in Patients with ROS1 Fusion-Positive NSCLC: Data from the Pivotal Phase 1/2 TRIDENT-1 Trial

Date: November 13, 2025 | 2:00 PM
When: Thursday, November 13 | 2 p.m. EST
Presenters:
Whitney Lewis, PharmD, BCOP | Bristol Myers Squibbs

Repotrectinib (Augtyro®) is offering new possibilities for patients with ROS1 fusion–positive NSCLC.
In this session, Whitney Lewis, PharmD, BCOP (Bristol Myers Squibb) will review data from the pivotal TRIDENT-1 trial and what it means for treatment decisions in real-world practice.

We’ll talk about:

  • How repotrectinib performs in treatment-naïve vs. pretreated patients
  • What the data show about CNS activity and resistance management
  • How its safety and efficacy compare to other ROS1-targeted therapies
  • Key factors to consider for sequencing and patient selection

For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.